Epigenetic deregulation of DNA repair and its potential for therapy.

Détails

ID Serval
serval:BIB_7A6172CF6A01
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Epigenetic deregulation of DNA repair and its potential for therapy.
Périodique
Clinical Cancer Research
Auteur(s)
Hegi M.E., Sciuscio D., Murat A., Levivier M., Stupp R.
ISSN
1078-0432
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
15
Numéro
16
Pages
5026-5031
Langue
anglais
Résumé
Epigenetic silencing of essential components of DNA repair pathways is a common event in many tumor types, and comprise O6-methylguanine-DNA methyltransferase (MGMT), human mut L homolog 1 (hMLH1), Werner syndrome gene (WRN), breast cancer susceptibility gene 1 (BRCA1), and genes of the Fanconi anemia pathway. Most interestingly, some of these alterations become the Achilles heel of the affected tumors upon treatment with certain classes of anticancer agents. That is, patients whose tumors carry such defects can be stratified for respective therapy rendering some classic DNA damaging agents, such as alkylators or DNA crosslinking agents, into "targeted therapies." Here we review some of the affected repair pathways that, when inactivated, sensitize the tumors to specific drugs and are thus exploitable for individualized therapy.
Pubmed
Web of science
Création de la notice
24/08/2009 13:11
Dernière modification de la notice
03/03/2018 18:33
Données d'usage